RecruitingPhase 3NCT05541276

MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children

MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children. The MELA-PAED Trial: a Randomized, Double-blind, Placebo-controlled Trial.


Sponsor

Rigshospitalet, Denmark

Enrollment

400 participants

Start Date

Jan 21, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Postoperative agitation and emergence delirium describe a spectrum of symptoms of early postoperative negative behavior, in which the child experiences a variety of behavioral disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. The symptoms are common with a reported incidence of approximately 25%. Some clinical trials have studied the effect of prophylactic oral melatonin for reducing the risk of emergence agitation in children, some finding a considerable dose-response effect. Melatonin has a low bio-availability of approximately 15 %. The safety of exogenous melatonin for pediatric patients has been studied with no apparent serious adverse effects, even at repeated short-term use of high doses of intravenous melatonin. The aim of this clinical trial is to investigate the prophylactic effects and safety of intravenous melatonin administered intraoperatively for prevention of postopreative agitation and emergence delirium in children after an elective surgical procedure. The study is designed as a randomised, double-blind, placebo-controlled clinical trial.


Eligibility

Min Age: 1 YearMax Age: 6 Years

Inclusion Criteria2

  • Patients aged 1-6 years
  • Elective surgical procedure of en axpected duration of at least 30 minutes in general anesthesia maintained with sevoflurane

Exclusion Criteria2

  • Any known allergy or contraindication to study treatment or excipåients
  • Current daily medication with melatonin

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMelatonin

Melatonin for injection 1 mg/mL

DRUGIsotonic sodium chloride solution

Sodium chloride 0.9 % for injection


Locations(1)

Department of Anesthesiology, Juliane Marie Center, Rigshospitalet

Copenhagen, Capital Region, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05541276


Related Trials